Facing the patent cliff: BMS, Amgen and Pfizer are all in response, Bojian may be acquired

For large biopharmaceutical companies, while "blockbuster" products bring huge benefits, they have to fight the patent cliff they face, and whether they can handle this problem well will determine the company's future destiny
.

Among the 19 large biopharmaceutical companies in the U.
S.
and Europe, Bristol-Myers Squibb, Amgen and Pfizer will face generic or biosimilar competition for most of their revenue in 2025, and the patent cliff will lead to related product revenue also falling will drop rapidly
.

By 2030, Bristol-Myers Squibb, Amgen, and Pfizer are likely to see generics cannibalize 47%, 29%, and 28% of their respective projected 2025 total revenue
.

01 Bristol-Myers Squibb: push new products to make up

Overall, 66% of Bristol-Myers Squibb's 2025 revenue will come from drugs facing a patent cliff between 2021 and 2030
.

Two small-molecule drugs, Eliquis and Revlimid, will lose more than 80% of their revenue between 2025 and 2030
.

Bristol-Myers Squibb also said that losses from 2020 to 2025 due to the expiration of the Revlimid patent will be about $12 billion to $14 billion, and the drug's patent will expire in 2022
.

02 Amgen: Active Trading Supplement

Amgen also has nine products facing patent expiry between 2021 and 2030
.

Otezla could lose 81% of its revenue, or nearly $2.
7 billion, between 2025 and 2030, as Shinji sold it to Amgen for $13.
4 billion in 2019 in a bid to win its opposition to its merger with Bristol-Myers Squibb Monopoly license
.

While Amgen faces stiff competition for these key products, the company's product line lacks dynamism
.

Amgen has made several small acquisitions in 2021
.

03 Pfizer: The most abundant cash and strong M&A firepower

Pfizer will lose patent protection on 11 important drugs by 2030
.
In addition to Eliquis, which is partnered with Bristol-Myers Squibb, the other most important product is breast cancer treatment Ibrance (piperociclib)
.
The two drugs are expected to account for 23% of Pfizer's revenue in 2025
.
Revenue losses for Eliquis and Ibrance will fall by 77% by 2030, to $6.
1 billion and $4.
8 billion, respectively
.

In addition, the prostate cancer drug Xtandi (enzalutamide) co-developed by Pfizer and Astellas will lose patent protection in the United States in 2027, and will rapidly lose 87% of revenue, or $1.
5 billion, between 2025 and 2030
.
Blockbuster transthyretin amyloidosis therapy Vyndaqel/Vyndamax (clofenac) will lose $2.
7 billion over the period, and another $1.
8 billion in lost revenue will come from the JAK inhibitor Xeljanz (tofacitinib)
.

Luckily for Pfizer, the company is generating significant revenue from the sale of COVID-19 products, including BioNTech's vaccine Comirnaty and the FDA's newly approved antiviral drug Paxlovid
.
Cash from COVID-19 products and the planned spin-off of Pfizer's consumer health joint venture with GlaxoSmithKline could give the company more M&A firepower to bolster its pipeline
.

Pfizer has already made progress on the deal
.
The company will acquire Arena Pharma for $6.
7 billion for etrasimod, an S1P modulator in development for a variety of inflammatory diseases
.
This is Pfizer's larger acquisition after the acquisition of Trillium for about $2.
26 billion in the summer of 2021, and it is estimated that this is only the beginning of Pfizer's acquisition
.

04 Bojian: Will it be acquired? !

In late December, the Korea Economic Daily reported, citing investment banking sources, that Samsung Group was in talks to buy Biogen for $42 billion
.
Although Samsung Group subsequently denied it, Bojian's development prospects are equally worrying
.

Tecfidera (dimethyl fumarate), the company's best-selling oral multiple sclerosis product, brought Biogen $3.
9 billion in revenue in 2020 (down 12% year-on-year), accounting for 36.
5% of the company's total revenue
.
The product is also facing a generic invasion, with Tecfidera's global sales falling 54% to $1.
47 billion in the first nine months of 2021
.
Another spinal muscular atrophy blockbuster product, Spinraza (Nosinagen sodium), saw a slight decline in sales, although it reached $2.
052 billion in 2020
.

Biogen expects to power its performance with Alzheimer's drug Aduhelm
.
Instead, the drug faced safety controversies and payer skepticism, and in its first quarter on the market, Aduhelm generated just $300,000 in revenue, well below expectations
.

Meanwhile, Biogen is preparing to cut jobs as part of a $500 million cost-cutting plan
.
Biogen is also halving the price of Aduhelm through January 1, 2022, to stimulate sales
.

The sales growth of Biogen's existing listed products lacks momentum, and the R&D pipeline has no bright spots.
Although the revenue of 13.
44 billion US dollars in 2020 is enough to make it a top 20 pharmaceutical company in the world, it may not be able to escape the fate of being acquired after all? !